Cellphire Therapeutics is a clinical stage Biotech believes no-one should die from controllable hemorrhage. We are revolutionizing bleeding treatment with platelet derived therapeutics. With a late stage first-to-market clinical asset & follow-on first-in-class assets with significant market opportunities; well-understood, derisked, scalable CMC; and addressing significant unmet needs in acute bleeding ($4 BN). First commercial launch in 2027 of our late stage lead asset has safety and efficacy proof points outside the US. Cellphire, led by a strong team with a track record of development and commercialization of assets >$4 Billion, has received non-dilutive funding in excess of $155 mm.